On August 30, Gelonghui announced that Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) reported revenue of approximately 2.143 billion yuan in the first half of 2024, a decrease of 6.99% year-on-year; the net income attributable to the shareholders of the listed company was approximately 0.405 billion yuan, a decrease of 35.15% year-on-year; with a basic EPS of 0.25 yuan.
健友股份(603707.SH)：上半年净利润约4.05亿元，同比减少35.15%
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): The net income in the first half of the year was approximately 0.405 billion yuan, a year-on-year decrease of 35.15%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.